NCT00569153已完成1 期
A Phase 1/2, Open-Label, Multiple-Dose Study of the Safety, Tolerability, and Pharmacokinetics of TAK-700 in Metastatic, Androgen-Independent Prostate Cancer Subjects
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 123
- 试验地点
- 19
- 主要终点
- Safety and tolerability of TAK-700 by evaluating adverse events, vital signs, physical examination findings, concomitant medications and laboratory tests.
研究概览
简要总结
The purpose of this study is to determine the safety and tolerability of TAK-700 in patients with asymptomatic metastatic, androgen independent prostate cancer.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- •Subject is male and at least 18 years of age.
- •Subject has histologically- or cytologically-confirmed prostate adenocarcinoma with metastatic, progressive disease while on androgen deprivation therapy.
- •Subject has radiograph-documented (computed tomography, magnetic resonance imaging or x-ray) metastatic disease.
- •Subject has undergone orchiectomy or is expected to continue receiving luteinizing hormone-releasing hormone analogue therapy, and has a testosterone level of <50 ng/dL at screening.
- •Subject has discontinued all antiandrogen therapy (within 30 days for flutamide and within 6 weeks for all others) prior to their first dose of study drug.
- •Subject has a prostate-specific antigen level ≥5 ng/mL.
- •Subject meets all screening laboratory values as specified in the protocol.
- •Subject has a screening ejection fraction that is above the lower limit of the institutional normal range.
- •Subject has ECOG performance status of 0 to
- •Subject has normal or, in the opinion of the investigator, clinically insignificant, physical examination findings, ECG and chest x-ray results.
- •Subjects, even if surgically sterilized (ie, status postvasectomy), who: agree to practice effective barrier contraception during the entire study treatment period and for 4 months after the last dose of study drug, or agree to completely abstain from heterosexual intercourse.
排除标准
- •Subject has known hypersensitivity to TAK-700 or related compounds.
- •Subject has received prior therapy with aminoglutethimide or ketoconazole within 30 days prior to the first dose of study drug.
- •Subject has received prior chemotherapy for prostate cancer.
- •Subject has received any investigational compound within 30 days prior to first dose of study drug.
- •Subject has received prior herbal product known to decrease prostate-specific antigen levels (eg, Saw Palmetto, PC-SPES) within 30 days prior to the first dose of study drug.
- •Subject has received radiation therapy for prostate cancer within 30 days prior to first dose of study drug.
- •Chronic therapy with oral or other systemically administered corticosteroids, such as prednisone, within 30 days prior to Screening. Chronic therapy is defined as the use of corticosteroids for more than 7 days within a 30-day period.
- •Subject has current spinal cord compression, current bilateral hydronephrosis, or current bladder neck outlet obstruction.
- •Subject has a history of adrenal insufficiency.
- •Subject has a history of myocardial infarction, ischaemic symptomatic heart disease, cardiac arrhythmias or thromboembolic events (eg, deep vein thrombosis, pulmonary embolism, or symptomatic cerebrovascular events), or any other cardiac condition (e.g., pericardial effusion restrictive cardiomyopathy) within 12 months prior to first dose of study drug.
- •Subject has any symptoms which the investigator deems related to prostate cancer, i.e., bone pain, pelvic pain.
- •Subject has a history of congestive heart failure (New York Heart Association Class II or greater.
- •Subject has history of another malignancy other than basal cell carcinoma or state 1 squamous cell carcinoma of the skin, within the last 5 years.
- •Subject has uncontrolled hypertension.
- •Subject is known to have HIV infection, chronic Hepatitis B or C or any other serious medical condition or psychiatric illness that might affect life expectancy or make it difficult to successfully manage and follow the subject according to protocol.
- •Subject is unable to understand verbal or written English or any other language for which a certified translation of the institutional review board (IRB)-approved informed consent has been provided.
- •Subject is unwilling or unable to comply with the protocol or cooperate fully with the investigator and site personnel.
研究组 & 干预措施
Arm 1 (TAK-700)
Experimental
干预措施: TAK-700 (Drug)
Arm 2 (TAK-700 at 400 mg & 5 mg prednisone)
Experimental
干预措施: TAK-700 (Drug)
Arm 3 (TAK-700 at 600 mg & 5 mg prednisone)
Experimental
干预措施: TAK-700 (Drug)
Arm 4 (TAK-700 at 600 mg)
Experimental
干预措施: TAK-700 (Drug)
结局指标
主要结局
Safety and tolerability of TAK-700 by evaluating adverse events, vital signs, physical examination findings, concomitant medications and laboratory tests.
时间窗: Cycle 1: Weeks 1, 2, 3 and 4, then every 4 weeks thereafter.
次要结局
- Efficacy and pharmacokinetics (PSA response and/or objective disease response)(Cycle 1: Weeks 1, 2, 3 and 4, then every 4 weeks thereafter.)
研究者
研究点 (19)
Loading locations...
相似试验
已完成
1 期
Safety, Tolerability and Pharmacokinetics of Escalating Single Doses of TAK-137 in Healthy ParticipantsDose Finding StudyNCT02334982Takeda47
终止
1 期
Safety, Tolerability, and Pharmacokinetics of Multiple Rising Doses of TAK-137 in Adults With Attention-Deficit/Hyperactivity Disorder.Attention-Deficit/Hyperactivity DisorderNCT02163915Takeda47
已完成
1 期
Phase 1 TAK-041 First-in-Human Safety, Tolerability, and Pharmacokinetics StudyHealthy VolunteersSchizophreniaNCT02748694Neurocrine Biosciences114
撤回
1 期
A Phase 1, Single and Multiple Dose Study of TAK-137Healthy Japanese Adult MaleNCT02322606Takeda
进行中（未招募）
3 期
A Study of TAK-279 in Participants With Moderate-to-Severe Plaque PsoriasisPlaque PsoriasisNCT06550076Takeda2,099